Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis

Abstract

Topical mechlorethamine remains one of the most effective therapies for the treatment of early- stage mycosis fungoides (MF) with overall response rates between 59% and 94.7%.1-3 Its use can be limited by the development of cutaneous reactions at sites of application.4 It is not uncommon for dermatitis to occur and lead to noncompliance to the treatment. During our clinical experience with mechlorethamine gel (Valchlor 0.016% gel [USA], Ledaga [chlormethine gel] [EU]), we have identified 3 presentations of contact dermatitis (CD) in patients undergoing therapy.

Topics & Concepts